[mrsD]

http://old.news.yahoo.com/s/nm/20111...algreen_pfizer

Several retail pharmacies are suing Pfizer for restricting generics for Effexor. It is so depressing!

[Dr. Smith]

I expect something similar to happen in '13 with Purdue Pharma (not to be confused with Purdue Farms - the chicken people ) when the Oxycontin patents expire. I totally expect them to claim that the new formulation (which most patients and doctors claim does not work as well, and does not prevent/deter abuse as claimed) constitutes a whole new patent, and try to extend it another 15-20 years (from the date of the formula change).

Profits:x 2
Patients: 0

Doc

[mrsD]

That may very well happen. That is how drug companies
continue with the big bucks!

The most famous at this was:

Furadantin (antibiotic mostly for kidney/bladder infections)
then became, Macrodantin (macrocrystals easier on stomach)
then became MacroBID ( another change in dosage release).
All containing the same drug. 30+ yrs on patent!

It is probably killing Pfizer that Lipitor goes generic in 2012.

We may see some very negative information released about statins after Lipitor goes GEQ. The parent company does not want damage/liability attaching to their drug when generics are sued. That is when SSRI negative studies that were held secretly by Glaxo and Lilly became available when Paxil and Prozac went GEQ.

[Lara]

http://www.healthiertalk.com/big-pha...d-history-4911

Big Pharma's new drug has a twisted history
By Dr. Allan Spreen on 11/09/2011

Big Pharma and Big Tobacco share the same bed

_____________________

just FYI - not much gets as bad as the mecamylamine hcl/Inversine debacle which I've been following for many years now ever since it was trialed in young children with Tourette's syndrome and a staffer from Layton BioScience was actually posting on some of the TS forums at the time attempting to market their medication. That was very strange!

Anyway, R.J. Reynolds/ Layton BioScience / Targacept / now I think they are Targacept/AstraZeneca
They keep changing their names and therefore keep changing their target population. smokers, tic disorders, depression, adhd etc etc Makes me sick.

http://www.ncbi.nlm.nih.gov/pubmed/11556635
J Am Acad Child Adolesc Psychiatry. 2001 Sep;40(9):1103-10.
Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder.
Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR.
Source

University of South Florida College of Medicine, Tampa 33613, USA.

Financial Disclosure: RDS, AAS, and PRS are inventors on a patent owned by the University of South Florida, which covers the use of nicotinic receptor antagonists for the treatment of nicotine-responsive neuropsychiatric disorders. RDS, AAS, PRS, and DVS have served as scientific consultants for Layton BioScience, Inc., who own the tradename and marketing rights to mecamylamine (Inversine®). PRS has also served on the board of directors for Layton BioScience, Inc.

Funded by University of South Florida I-4 Corridor Project
Layton BioScience, Inc.

RDS = R. Douglas Shytle
AAS = Archie A. Silver
DVS = David V. Sheehan
PRS = Paul R. Sanberg